Airain ltd purchased a new position in Alkermes Plc (NASDAQ:ALKS) during the first quarter, Holdings Channel reports. The fund purchased 82,954 shares of the company’s stock, valued at approximately $4,853,000.
A number of other institutional investors also recently added to or reduced their stakes in the company. Massey Quick & Co. LLC bought a new position in Alkermes Plc during the fourth quarter worth $111,000. TLP Group LLC bought a new position in Alkermes Plc during the third quarter worth $187,000. Greenwood Capital Associates LLC bought a new position in Alkermes Plc during the fourth quarter worth $202,000. Mn Services Vermogensbeheer B.V. boosted its position in Alkermes Plc by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock worth $222,000 after buying an additional 224 shares in the last quarter. Finally, Spot Trading L.L.C bought a new position in Alkermes Plc during the third quarter worth $267,000. Hedge funds and other institutional investors own 95.52% of the company’s stock.
Alkermes Plc (NASDAQ:ALKS) traded down 0.03% during trading on Friday, hitting $57.91. The stock had a trading volume of 728,646 shares. Alkermes Plc has a 52 week low of $39.65 and a 52 week high of $62.50. The firm’s market cap is $8.87 billion. The company’s 50-day moving average is $57.81 and its 200 day moving average is $56.90.
Alkermes Plc (NASDAQ:ALKS) last released its earnings results on Thursday, April 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.07. The business had revenue of $191.80 million during the quarter, compared to analyst estimates of $195.79 million. Alkermes Plc had a negative net margin of 36.92% and a negative return on equity of 12.75%. The business’s quarterly revenue was up 22.3% compared to the same quarter last year. During the same period last year, the business earned ($0.16) EPS. Equities analysts expect that Alkermes Plc will post ($0.04) EPS for the current fiscal year.
WARNING: This article was originally posted by Mideast Time and is the sole property of of Mideast Time. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.mideasttime.com/82954-shares-in-alkermes-plc-alks-acquired-by-airain-ltd/1709194.html.
A number of equities analysts have weighed in on the company. TheStreet upgraded Alkermes Plc from a “d+” rating to a “c” rating in a report on Wednesday, February 15th. Morgan Stanley restated an “equal weight” rating and issued a $62.00 price target on shares of Alkermes Plc in a report on Monday, April 24th. Cowen and Company restated a “positive” rating and issued a $65.00 price target on shares of Alkermes Plc in a report on Tuesday, March 21st. Credit Suisse Group AG set a $70.00 price target on Alkermes Plc and gave the stock a “buy” rating in a report on Friday. Finally, Jefferies Group LLC restated a “buy” rating and issued a $70.00 price target on shares of Alkermes Plc in a report on Monday, April 3rd. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $63.55.
In other Alkermes Plc news, SVP Michael J. Landine sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $57.23, for a total value of $572,300.00. Following the sale, the senior vice president now owns 167,370 shares of the company’s stock, valued at approximately $9,578,585.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard F. Pops sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $58.19, for a total value of $2,909,500.00. Following the completion of the sale, the director now directly owns 680,406 shares in the company, valued at approximately $39,592,825.14. The disclosure for this sale can be found here. Insiders sold a total of 199,800 shares of company stock worth $11,638,101 in the last ninety days. Insiders own 4.75% of the company’s stock.
Alkermes Plc Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).
Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.